The generic version of Onglyza is expected to be released after 30 November, 2028. This is due to the expiration of the patent US7951400 titled 'Coated tablet formulation and method' on this date.
Onglyza is used to treat type II diabetes. It works by administering Saxagliptin either alone or in combination with other drugs like insulin, metformin, a thiazolidinedione, glyburide or metformin plus a sulfonylurea.
Onglyza has two patents, of which one has already expired. The remaining patent (US7951400) is set to expire on 30 November, 2028, post which Onglyza generics could be available. Below are the details of the patent: